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A B S T R A C T
Research during past decades made it evident that complement is involved in more tasks than ﬁghting infections,
but has important roles in other immune surveillance and housekeeping functions. If the balance between
complement activation and regulation is out of tune, however, complement can quickly turn against the host and
contribute to adverse processes that result in various clinical conditions. Whereas clinical awareness was initially
focused on complement deﬁciencies, excessive activation and insuﬃcient regulation are frequently the dominant
factors in complement-related disorders. The individual complement proﬁle of a patient often determines the
course and severity of the disease, and the pathophysiological involvement of complement may be highly
diverse. As a consequence, complement assays have evolved as essential tools not only in initial diagnosis but
also for following disease progression and for monitoring complement-targeted therapies, which become
increasingly available in routine clinical use. We herein review the current state of complement-directed drug
candidates in clinical evaluation and provide an overview of extended indications considered for the FDA-
approved inhibitor eculizumab. Furthermore we review the literature describing cases reports and case series
where eculizumab has been used “oﬀ-label”. Finally, we give a summary of the currently available tests to
measure complement proﬁles and discuss their suitability in diagnostics and treatment monitoring. With
complement ﬁnally entering the clinical arena, there are intriguing opportunities for treating complement-
mediated diseases. However, this progress also requires a new awareness about complement pathophysiology,
adequate diagnostic tools and suitable treatment options among clinicians treating patients with such disorders.
1. The changing landscape of complement in disease and therapy
The past few decades have led to a profound shift in our perception
of the human complement system. Commonly known as an innate
immunity segment of the host defense system that protects our bodies
from invading microbes and other threats, it has become increasingly
evident that complement has important roles in other immune surveil-
lance and housekeeping tasks but also contributes to a wide and diverse
range of clinical disorders (Ricklin et al., 2010; Ricklin et al., 2016).
The reason for this ambivalence of complement in physiological and
pathophysiological processes is founded in its functional organization.
In order to provide instant and eﬀective protection against foreign
intruders, complement invokes an elaborate network of soluble and cell
surface-bound components, pattern-recognition proteins (PRP), pro-
teases, receptors, eﬀectors and regulators (Fig. 1) (Merle et al., 2015a;
Ricklin et al., 2016). Under normal circumstances, specialized PRP
detect danger-associated patterns on particle surfaces and initiate an
enzymatic cascade that leads to the covalent attachment of opsonins
(i.e. C4b and C3b proteins) via one of three principal initiation routes
(termed classical, lectin and alternative pathway; CP, LP and AP,
respectively). On the surface, C3b and C4b form enzyme complexes
(termed convertases) that cleave the abundant plasma protein C3 into
C3b than can again be deposited and form convertases, thereby fueling
the rapid ampliﬁcation of opsonization on unprotected surfaces. In
many cases, this AP-mediated ampliﬁcation acts as the major driving
force and triage point of complement activation via any initiation
pathway (Harboe et al., 2009; Harboe et al., 2004).
With progressing ampliﬁcation, the convertases start cleaving the
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C5 component, a fragment of which initiates the formation of lytic
membrane attack complexes (MAC; C5b-9n) that directly destroy or
damage susceptible cells. The activation of C3 and C5 also liberates
potent chemotactic fragments (i.e., the anaphylatoxins C3a and C5a)
that recruit immune cells to the site of activation and prime them.
Professional phagocytes recognize opsonins on the attacked particles
via complement receptors (CR), thereby mediating their phagocytic
removal. Finally, complement eﬀectors are shaping the downstream
immune reaction by lowering the threshold of B cell activation and
mediating T cell responses, among others (Merle et al., 2015b; Ricklin
et al., 2016). In order to provide such broad and instant reactivity in
case of threats, the complement system must not be cell-speciﬁc and
opsonization may occasionally occur on host tissue. Our cells are
generally protected from ampliﬁcation and eﬀector insult by a panel
of complement regulators, which are expressed on their surface or
recruited from circulation (Schmidt et al., 2016). However, if the
balance between complement activation and regulation is out of tune,
complement can quickly turn against the host and trigger and/or
exacerbate adverse processes that result in diseases and clinical
complications (Ricklin and Lambris 2013; Ricklin et al., 2016).
Whereas the pathophysiological involvement has long been recog-
nized, it is only now that the extent of this ‘dark side of complement’
becomes apparent. Initial clinical awareness primarily focused on
complement deﬁciencies, yet excessive activation and insuﬃcient
regulation are by far more common drivers of complement-mediated
disorders. In principle, any foreign or altered/damaged host cell surface
can trigger a complement response (Ricklin et al., 2016). The sudden
exposure to a massive amount of danger pattern, as in the case of sepsis
or trauma, can overwhelm the system and fuel a vicious cycle that
causes tissue damage and systemic inﬂammation. Similarly, transplants
or biomedical materials often trigger an adverse complement response
that aﬀect both the clinical and functional outcome of the treatment.
And even though complement typically helps clearing cellular debris,
the inability to do so eﬃciently can trap complement in an inﬂamma-
tory state, as obvious in cases such as atherosclerosis or Alzheimer’s
disease. Any imbalance between activating and regulatory mechanism,
Fig. 1. Schematic overview of complement activation on foreign particles or damaged host cell surfaces. Binding of pattern recognition proteins (PRP) to danger markers initiates the cascade via
the classical pathway (CP), where C1q recognizes antibodies but also mediators such as C-reactive protein (CRP) and serum amyloid P (SAP), or the lectin pathway (LP) with the main
PRPs being MBL, ﬁcolins and collectins. This leads to formation of CP/LP C3 convertases that cleave the abundant plasma protein C3 to C3a and C3b. Whereas C3a has
immunomodulatory functions, the opsonin C3b can be covalently deposited on the triggering surface and form alternative pathway (AP) C3 convertases that cleave more C3 and, in
absence of regulators, fuel an ampliﬁcation loop that leads to rapid opsonization stabilized by properdin (FP), the only complement regulator with enhancing eﬀects. The assembly of C5
convertases (e.g., C3bBb3bP) allows cleavage of C5 into the pro-inﬂammatory anaphylatoxin C5a and C5b. C5a is a highly potent proinﬂammatory mediator that activates C5a receptor
(C5aR) 1, but also binds to the regulatory C5aR2, which might counteract the C5aR1 eﬀects. C5b initiates the assembly of the terminal C5b-9 complex (TCC) which exists in two forms:
the membrane attack complexes (MAC) when inserted into a membrane and the soluble sC5b-9 when formed in the ﬂuid-phase. Whereas MAC may exert lysis of certain bacteria (e.g.
Neisseria) or cell death (typically red cells), it also induces inﬂammation during sub-lytic cell activation. The opsonins C3b and its degradation products iC3b and C3dg bind to
complement receptors (CR) on immune cells and facilitate adherence (C3b to CR1), phagocytosis (iC3b to CR3 and CR4), or mediate adaptive immune responses (iC3b and C3dg to CR2).
Complement regulators are crucial to keep the system under control. Soluble regulators include C1-INH, C4b-bining protein (C4BP), Factor I (FI), Factor H (FH), anaphylatoxin inhibitors
(AI, comprising carboxypeptidases), vitronectin (Vn) and clusterin (Cl). Membrane regulators include CR1, membrane cofactor protein, (MCP), and decay accelerating factor (DAF) at the
level of C4 and C3, by destabilizing convertases and degrading opsonins, and CD59 at the level of C8 and C9 by preventing MAC formation.
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often caused by genetic alteration in individual components, can
facilitate and accelerate disease processes and even act as causal factor
of some (Harris et al., 2012; Ricklin et al., 2016). The eyes and kidneys
appear to be particularly susceptible to the consequences of dysregu-
lated complement as evidenced by examples such as age-related
macular degeneration (AMD) and atypical hemolytic uremic syndrome
(aHUS), respectively. Due to the upstream placement of complement in
danger recognition and defense coordination, inappropriate comple-
ment activation typically starts involving downstream crosstalk pro-
cesses that contribute to inﬂammation and thrombosis (Foley 2016).
With increasing genetic and molecular insight into complement-
mediated pathological processes we realize that the exact involvement
of complement pathways and components is highly distinct between
individual diseases (Ricklin et al., 2016). Even more importantly, the
same disease spectrum may be caused and shaped by a broad variety of
diﬀerent alterations in complement activators and/or regulators. The
individual complement proﬁle of a patient (sometimes referred to as
“complotype”) often determines the course and severity of the disease
(Harris et al., 2012). Disorders such as AMD, aHUS or C3 glomerulo-
pathy (C3G) are among the most well-described examples in this
context (Nester et al., 2015; van Lookeren Campagne et al., 2016;
Zipfel et al., 2015). Profound and quantitative knowledge of the plasma
levels and genetic proﬁle of individual components and the overall
activity of the cascade therefore become increasingly important for
facilitating clinical diagnoses and allow for an eﬃcient monitoring of
disease progression. The recent surge of complement-targeted therapies
in a variety of diseases (see below) puts an even stronger emphasis on
the need for reliable diagnostic tools (Morgan and Harris 2015; Ricklin
and Lambris 2016b). In the case of clinical trials, they allow for the
much-needed patient stratiﬁcation and provide a critical tool for
assessing the achievement of clinical endpoint criteria. Even after
approval of complement drugs, proper diagnostics remains essential
for monitoring treatment progress and deciding about adjustments of
the medication. The following sections therefore provide an overview
and speciﬁc examples of the use of complement diagnostics in the
clinical and therapeutic context and summarize established and emer-
ging concepts of assessing a patient’s complement proﬁle.
2. Complement-targeted treatments entering clinical evaluation
The system’s upstream involvement in a broad range of disease
processes renders complement an intriguing and promising target for
therapeutic intervention, with indications ranging from inﬂammatory
and age-related diseases to biomaterial- and transplant-induced com-
plications (Morgan and Harris 2015; Ricklin and Lambris 2016b).
Whereas early eﬀorts in complement drug discovery were hampered
by limited molecular insight, technical challenges and safety concerns,
profound progress in all these areas has paved the way to a newfound
conﬁdence in this approach and led to a surge in novel complement-
targeting concepts (Morgan and Harris 2015; Ricklin and Lambris
2016b). Key to this development has certainly been the availability of
ﬁrst complement drugs in the clinic, in particular the therapeutic anti-
C5 antibody eculizumab (Soliris®, Alexion Pharmaceuticals), which
allowed to gain clinical experience and extend the spectrum of
indications. Although the clinical and commercial success of eculizu-
mab has fueled an interest in developing other C5 inhibitors, the
knowledge about the highly distinct involvement of complement in
disease processes described above has led to the realization that the
diversity of pathomechanisms requires a similar diversity in therapeutic
intervention points.
After years of development, more than a dozen candidate drugs
covering a wide range of the complement cascade are meanwhile being
evaluated in clinical trials (Tables 1 and 2). They not only show a broad
variety in their therapeutic target but also in the use of molecular
entities ranging from small molecules and peptides to proteins, anti-
bodies and oligonucleotides (Ricklin and Lambris 2016a). Whereas
most of the currently evaluated drug candidates act as protein–protein
interaction inhibitors, some are based on physiological regulators or
impair the production of complement component on the genetic level.
Even though established complement diseases such as AMD, aHUS and
paroxysmal nocturnal hemoglobinuria (PNH) remain in the focus of the
indication spectrum, several candidates explore novel or hitherto
challenging disease areas (e.g., transplantation or sepsis), thereby
helping to foster our knowledge about the possibilities and limitation
of therapeutic complement modulation. In this context, it is important
that more than ten years after its approval, eculizumab is still enrolled
in a variety of clinical trials to assess the potential of expanding the
drug’s indication list (Table 2). Similar is true for C1-inhibitor (C1-INH)
preparations (Table 1). Notably, C1-INH should be considered a
“plasma cascade inhibitor” rather than a complement-speciﬁc thera-
peutic, since the inhibitory actions of this physiological regulator reach
beyond complement; indeed they might be even more important in the
kallikrein-kinin system by reducing formation of bradykinin and in the
FXII-mediated intrinsic activation of the coagulation system (Zeerleder
2011).
In its current state, therapeutic complement inhibition covers an
impressive breath of concepts and approaches. This includes the
treatment of chronic, episodic and/or acute disorders, the local or
systemic administration of therapeutic entities, the targeting of initia-
tion, ampliﬁcation or eﬀector stages, and the intervention at the protein
and gene level. It appears logical, therefore, that such a diversity of
indications and approaches requires highly speciﬁc considerations
when it comes to the planning of clinical development plans and the
evaluation of therapeutic success. Whereas many of the previous
obstacles in complement drug discovery have meanwhile been re-
solved, the selection of suitable indications and patient populations has
emerged as a new challenge (Ricklin and Lambris 2016b). An impress-
ive example in this context is AMD. Genome-wide association studies
identifying the complement regulator factor H (FH) as major risk factor
for disease progression (Hageman et al., 2005), sparked a sudden
interest in this indication, initial complement-focused intervention
studies were of limited success. Intriguingly, a recent phase 2 trial
with the anti-Factor D (FD) antibody lampalizumab (Genentech)
revealed that patients carrying an additional complement variant on
top of the known FH Y402H polymorphism were beneﬁting much more
from the treatment (Ehmann and Regillo 2016) (see details below). This
underscores the critical signiﬁcance of patient stratiﬁcation in planning
successful clinical trials. In this context, diagnostic and genetic methods
and biomarker analysis become increasingly important as decision-
making, stratiﬁcation, and monitoring tools (Mollnes et al., 2007). At
some point, they may even pave the way to precision medicine
approaches for complement-targeted therapies. Fortunately, the ﬁeld
of complement diagnostics has drastically evolved in the wake of the
recent progress in complement research, and oﬀers a wide range of
tools to assess the genetic, molecular and functional complement proﬁle
of a patient.
3. The importance of genetic biomarkers in clinical trials: the case
of lampalizumab
The above-mentioned case of Genentech’s lampalizumab illustrates
several important aspects of current complement-targeted drug dis-
covery. The drug candidate targets the serine protease FD, which
constitutes a bottle neck in the AP-driven ampliﬁcation loop due to
its role to transform the pro-convertase (C3bB) into the active AP C3
convertase (C3bBb). Even though serine proteases are considered
druggable targets and FD has early been on the radar of therapeutic
complement modulation, initial eﬀorts have been challenging due to
limited septicity of small molecule candidates and pharmacokinetic
challenges caused by the rapid systemic turnover of FD (Ricklin and
Lambris 2007). Lampalizumab originated from one of the antibody
development programs by Tanox, with their anti-FD candidate (TNX-
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224) being transferred to Genentech after the company’s acquisition in
2007 (Ricklin and Lambris 2007). The clinical candidate is a humanized
antigen-binding fragment (Fab) of an IgG1 antibody.
It was later described that lampalizumab, rather than acting on the
catalytic center of the protease, tightly binds to an exosite of FD that
prevents its binding to the pro-convertase (Katschke et al., 2012).
Geographic atrophy in connection with dry forms of AMD is the only
indication for which lampalizumab is currently in clinical development,
which may at least partially be related to pharmacokinetic restrictions.
Whereas the anti-FD Fab was shown to be cleared from systemic
circulation within a few hours, the elimination half-life in the eye
extends beyond two days after intravitreal injection (Loyet et al.,
2014b). The local administration of lampalizumab into the eye also
takes away some emphasis on safety considerations, since the low
plasma concentrations after intravitreal injections are not expected to
signiﬁcantly aﬀect systemic complement activity (Loyet et al., 2014a).
In a phase 1 study (NCT00973011), lampalizumab was found to be
safe and well tolerated, and was subsequently evaluated in phase 2
trials. In the MAHALO study (NCT01229215, NCT01602120), 129
patients were enrolled to receive the drug or a sham treatment either
monthly or bimonthly. Although the oﬃcial results remain to be
published (Boyer et al., 2016), reports showed that the treatment
success (measured as reduction of geographic atrophy progression) was
approximately 20% overall, whereas a subgroup of patients carrying a
Factor I polymorphism showed a signiﬁcantly stronger eﬀect (44%)
(Holz et al., 2014). Interestingly, genotyping analysis of enrolled
patients receiving sham treatment revealed that almost all patients
were carriers of FH and/or C2/FB polymorphisms; whereas an addi-
tional C3 polymorphism did not notably aﬀect disease progression,
those patients carrying the FI polymorphism experienced an almost
50% more rapid growth of the geographical atrophy region during the
study (Yaspan et al., 2014). Two large, identical phase 3 studies
(Chroma, Spectri; Table 1) involving close to 1000 patients are
currently ongoing with results expected by the end of 2017. It will be
important to see how much the genetic background of patients
inﬂuenced treatment success and whether this may have implications
for therapeutic recommendations in case of approval.
4. Expanding indications case by case: the extended oﬀ-label use
of eculizumab
Eculizumab, the humanized monoclonal IgG2/4-antibody targeting
C5 was approved by the United States Food and Drug Administration
(FDA) and the European Medicines Agency for the treatment of PNH in
2007 and aHUS in 2011. During the time this drug has been available
for these two rare diseases, the eculizumab usage for oﬀ-label indica-
tions has been extensive. A recent report from France revealed that the
oﬀ-label administration of eculizumab exceeded 50% of the drugs’s
total consumption in the period from 2011 to 2013 (Castaneda-
Sanabria et al., 2016). Although this number is large and probably
not representative for all countries, it clearly demonstrates a growing
medical knowledge, faith and willingness to adopt complement inhibi-
tory therapy to other patients groups.
Based on a literature search in PubMed including case reports and
case series we compiled an overview of the oﬀ-label use of eculizumab,
categorized into diﬀerent disease entities (Table 3). The search revealed
106 papers documenting oﬀ-label use in at least 25 diﬀerent conditions
(a complete list of the conditions and corresponding references is found
in Supplementary Table 1). Even without considering the ongoing
clinical trials with eculizumab, listed in Table 2, or showing all
published reports and case series, this overview provides an impression
of the comprehensive oﬀ-label use of this anti-C5 antibody. Although
the question may arise whether such extensive oﬀ-label administration
without fully relying on evidence-based medicine represents good
medical practice, the reasons for this development are diverse. Indeed
part of the eculizumab use is implemented in clinical trials (e.g.
myastenia gravis and cold agglutination diseases; Table 2), whereas
the casuistry-based usage often occurs in critical clinical situations
where the patients have nothing to lose and the clinicians are standing
with their back against the wall (Barratt-Due et al., 2016). Furthermore,
Table 1
Complement therapeutics targeting complement initiation and ampliﬁcation in clinical trials (with an emphasis on ongoing or recently completed trials listed in the ClinicalTrials.gov
database; range 2015-present).
Target Drug/Candidate (Company) Entity1 Clinical Phase (Trial No.)2 Indications3
C1r, C1s, Cinryze (Shire)4 Pro P1 (NCT02435732) Transplantation
MASPs P3 (NCT02547220) Transplantation
Berinert (CSL Behring)4 Pro P1/2 (NCT02134314) Transplantation
P2 (NCT02936479) Transplantation
Cetor (Sanquin)4 Pro P3 (NCT01275976) term Trauma/Sepsis
P2 (NCT02251041) Transplantation
Ruconest/Conestat alfa4 (Pharming) Pro P2 (NCT02869347) Contrast-induced nephropathy
C1s TNT009 (True North) Ab P1 (NCT02502903) CAD, BP, AIHA, ESRD
MASP-2 OMS721 (Omeros) Ab P2 (NCT02222545) TMA
P2 (NCT02682407) IgAN, LN, MN, C3G
FP CLG561 (Novartis) Ab P2 (NCT02515942) AMD (GA)
C3 AMY-101 (Amyndas) Pep P1 (N/A) C3G, Transplantation
APL-1 (Apellis) Pep P1 (N/A) COPD
APL-2 (Apellis) Pep P1 (NCT02588833) PNH
P1 (NCT02264639) PNH (add-on)
P1 (NCT02461771) comp AMD (CNV)
P2 (NCT02503332) AMD (GA)
Conver-tases Mirococept (MRC) Pro P3 (EMPIRIKAL, ISRCTN49958194) Transplantation
FD Lampalizumab (Genentech) Ab P2 (NCT02288559) AMD (GA)
P3 (NCT02745119) AMD (GA)
P3 (NCT02247531) AMD (GA)
P3 (NCT02247479) AMD (GA)
ACH-4471 (Achillion) SM P1 (ACTRN12616000082404p) PNH
P2 (NCT03053102) PNH
11Abbreviations: Ab, antibody; Pep, peptide; Pro, protein; SM, small molecule; 2Abbreviations: P1-3, clinical phase 1–3; comp, completed; term, terminated. 3Abbreviations: AIHA,
autoimmune hemolytic anemia; AMD, age-related macular degeneration; BP, bullous pemphigoid; C3G, C3 glomerulopathy; CAD, cold agglutinin disease; CNV, choroidal
neovascularization; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; GA, geographic athrophy; IgAN, IgA nephropathy; LN, lupus nephritis; MN,
membranous nephropathy; PNH, paroxysmal nocturnal hemoglobinuria; TMA, thrombotic microangiopathies. 4C1-INH preparations are already approved for hereditary angioedema;
potential post-approval trials for the primary indications of the C1-INH drugs are not shown.
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almost all diseases listed in Table 3 are conditions in which complement
appears to play a key role in the pathophysiology, giving a theoretical
foundation for testing the eﬃcacy of eculizumab. Randomized clinical
trials will for most of these diseases not be possible because they are
rare and featured by a complex heterogeneity. Thus, case series and
case reports deﬁnitely represent a valuable contribution to new and
important knowledge. Still, it is important to be aware that case-based
literature generally reﬂects a substantial publication bias, since those
cases with positive outcome are much more likely both to be submitted
and to be accepted for publication, than those with negative results.
Especially in exploratory cases, the proper assessment of a patient’s
complement status and monitoring of therapeutic progress is essential
for ensuring a high quality and clinical value of extended-use case
studies.
5. An evolving need for reliable diagnostic and monitoring tools
The arsenal of diagnostic tools to evaluate complement proﬁles and
activities have greatly expanded over the past few decades. Several
comprehensive reviews on complement tests and diagnostics have been
published in recent years the last years and we here only refer to some
selected reviews published after 2005 for further reading (Harboe et al.,
2011; Mollnes et al., 2007; Nilsson and Ekdahl 2012; Oppermann and
Wurzner 2010; Prohaszka et al., 2016). An overview of the major
classes of complement diagnostic approaches is presented in Fig. 2.
Herein we will focus on assays that might be useful in diagnosis of
diseases where complement is suggested to be a substantial part of the
pathogenesis, and thus are candidates for future complement inhibitory
therapy. Furthermore, we will emphasize on those assays that might be
best suited for therapeutic monitoring. Since eculizumab is the only
FDA-approved speciﬁc complement inhibitory drug on the marked, we
will focus on assays related to C5 function. Notably, these assays may be
used on a broad basis also for future drugs, both those targeting C5 and
other central components including the main component C3, as well as
speciﬁc targets within the CP, LP and AP branches of the cascade.
The considerable number of assays that are currently used for
investigating the complement system can be divided into the following
groups: 1) screening of total functional complement activity; 2)
quantiﬁcation of single components; 3) measuring functional activity
of single components; 4) quantiﬁcation of complement activation
products; 5) detection of autoantibodies to complement components;
6) assessing cell surface expression and tissue deposition of complement
proteins or fragments; 7) determining genetic proﬁles, and ﬁnally; 8)
the use of novel, though not yet well established and standardized,
Table 2
Complement therapeutics targeting terminal complement pathways in clinical trials (with an emphasis on ongoing or recently completed trials listed in the ClinicalTrials.gov database;
range 2015-present).
Target Drug/Candidate (Company) Entity1 Clinical Phase (Trial No.)2 Indications3
C5 Soliris/Eculizumab 4 Ab P2 (NCT01303952) comp CAD
(Alexion) P2 (NCT02093533) MPGN
P2 (NCT01567085) Transplantation
P2 (NCT01919346) Transplantation
P2 (NCT01895127) term Transplantation
P2 (NCT01399593) term Transplantation
P2/3 (NCT02145182) comp Transplantation
P2/3 (NCT01106027) Transplantation
P3 (NCT02301624) Myasthenia gravis
P3 (NCT01997229) comp Myasthenia gravis
P3 (NCT01892345) Neuromyelitis optica
ALXN1210 (Alexion) Ab P1/2 (NCT02598583) PNH
P2 (NCT02605993) PNH
P3 (NCT02946463) PNH (naïve)
P3 (NCT03056040) PNH (treated)
P3 (NCT02949128) aHUS (naïve)
Tesidolumab/LFG316 (Novartis/Morphosys) Ab P1 (NCT02878616) Transplantation
P2 (NCT02763644) TMA
P2 (NCT01527500) comp AMD (GA)
P2 (NCT02515942) AMD
P2 (NCT02534909) PNH
P2 (NCT01526889) Uveitis/Panuveitis
Coversin (Akari) Pro P2 (NCT02591862) PNH
RA101495 (Ra Pharma) Pep P1 (ACTRN12615001143516) PNH
P2 (NCT03030183) PNH (poor responders)
P2 (NCT03078582) PNH
Zimura Nuc P2 (NCT02397954) comp IPCV
(Ophthotech) P2/3 (NCT02686658) AMD
ALNeCC5 Nuc P1/2 (NCT02352493) PNH
(Alnylam)
C5a IFX-1 Ab P2 (NCT02246595) comp Sepsis
(InﬂaRx) P2 (NCT02866825) comp SIRS
P2 (NCT03001622) Hidradenitis suppurativa
ALXN1007 Ab P2 (NCT02245412) term GVHD
(Alexion) P2 (NCT02128269) comp APS
C5aR1 Avacopan/CCX168 (Chemocentryx) SM P2 (NCT02222155) comp ANCA-vasculitis
P2 (NCT01363388) comp ANCA-vasculitis
P2 (NCT02464891) term aHUS
P2 (NCT02384317) comp IgAN
P3 (NCT02994927) ANCA-vasculitis
1Abbreviations: Ab, antibody; Nuc, nucleotide; Pep, peptide; Pro, protein; SM, small molecule; 2Abbreviations: P1-3, clinical phase 1–3; comp, completed; term, terminated.
3Abbeviations: aHUS, atypical hemolytic uremic syndrome; AMD, age-related macular degeneration; APS, antiphospholipid syndrome; CAD, cold agglutinin disease; GA, geographic
athrophy; GVHD, graft versus host disease; IgAN, IgA nephropathy; IPCV, idopathic polypoidal choroidal vasculopathy; PNH, paroxysmal nocturnal hemoglobinuria; SIRS, systemic
inﬂammatory response syndrome; TMA, thrombotic microangiopathies. 4Eculizumab is already approved for PNH and aHUS; potential post-approval trials for the primary indications are
not listed.
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assays to monitor eculizumab treatment (Table 4). Note, from this table
it is crucially important how the samples are obtained and handled for
each of the assay groups.
5.1. Screening of total complement activity
The main indication for using screening assays for total complement
activity is to detect complement deﬁciencies. Such deﬁciencies can be
genetic, acquired or a consequence of complement inhibitory therapy.
These tests detect the total amount of active complement compo-
nents present in a freshly drawn serum sample and reﬂect the potential
of a person’s serum to induce complement activation in vitro after
adding it to a complement activator. The traditional assays in this group
are the CH50 and AH50 lytic assays, based on either the lysis of
antibody sensitized sheep erythrocytes (CH50 for detecting CP activity)
or the lysis of untreated rabbit erythrocytes (AH50 for the of AP
activity) (Joiner et al., 1983; Mayer 1958). In both cases the functional
readout is the lytic destruction of erythrocytes upon membrane
insertion of C5b-9 (MAC). In recent years, novel ELISA-based assays
have been developed, which more speciﬁcally detect complement
activation through CP, LP and AP (Seelen et al., 2005); the “comple-
ment system screen” test by Wieslab is one widely-used example
(Fig. 3A). Although the readout target of these ELISAs is principally
the same as for the lytic assays, it is based on detecting full assembly of
C5b-9 by using an antibody to a C9 neoantigen when serum is added to
micro-titer wells coated with the activation agent for the diﬀerent
pathways (e.g., IgM for CP, mannan for LP, and lipopolysaccharides for
AP).
Thus, the C5b-9 molecule is generated in vitro as an endpoint of the
complement cascade in these assays and reﬂects the total amount of
native components present in the sample. If all components are present
and with intact function, the lytic assays will reveal normal lysis of red
cells and the ELISA assays normal deposition of C5b-9. One exception is
that properdin deﬁciency is frequently not detected in the AH50 assay
in contrast to the complement screen assay (Seelen et al., 2005). If
eculizumab is present C5 activation will be prevented and C5b-9
deposition in ELISA will be reduced (Fig. 3, B, a-d). If all C5 molecules
are inhibited (Fig. 3B, b-d), the phenotype will be identical to a genetic
C5 deﬁciency and the lysis respective C5b-9 deposition will be
abolished in these assays. The terminal C5b-9 complement complex
exists in two forms, the MAC and the soluble form (sC5b-9). The in vitro
generated surface-bound C5b-9 must not be confused with sC5b-9,
which is found in plasma and if increased is a useful marker of
complement activation in vivo reﬂecting diseases with disturbed
complement function. sC5b-9 can be quantiﬁed by ELISA (Fig. 3C)
and is based on the same C9 neoepitope principle; in this case, the
complex that is already present in plasma is captured by the antibody
coated to the plate (see below). In the case of eﬃcient C5 blockade,
there should ideally be no sC5b-9 present.
5.2. Quantiﬁcation of single components
Measurement of single components like C3 and C4 are usually
performed with nephelometry or similar techniques using polyclonal
antibodies. In such methods the total amount of the antigen present is
detected without distinguishing the native component from the activa-
tion product. Thus, the sampling and storage conditions are not that
critical for these assays as it is for the functional assay. The level of the
single components will depend on several factors including synthesis
and secretion (most components are decreased in liver failure), acute
phase reaction (most components increase moderately) or in vivo
activation (consumption with reduced levels). The concentration will
reﬂect the sum of these factors and interpretation of the results should
therefore be made with caution. A low concentration does not
necessarily imply increased complement activation in vivo.
Supplemental information from activation product tests will be needed
to document a systemic increase in activation (see below).
5.3. Functional activity of single components
Normal concentrations of single components do not exclude func-
tional defects. Thus, if a functional defect is suspected or needs to be
ruled out, the functional activity can be tested. This has typically been
done using sera depleted of the actual component and with the patient’s
fresh serum added, to see whether the activity can be restored, e.g. by
using hemolysis as readout. In recent years, genetic tests detecting
variants and mutations known to compromise the function of the
protein have largely replaced the functional protein assays. These tests
will not only reveal “loss-of-function” but also “gain-of-function” of
single components, like C3 “gain-of-function” associated with aHUS
(Roumenina et al., 2012), similar to the typical “loss-of-function of
regulatory proteins (Nester et al., 2015).
5.4. Quantiﬁcation of complement activation products
Monoclonal antibodies to neoepitopes exposed in the activation
product but hidden in the native component enable speciﬁc quantiﬁca-
tion of activation products. Such assays are typically sandwich techni-
ques like ELISA or luminex, using the anti-neoepitope antibody as
capture antibody. A number of activation products can be tested, most
of them available as commercial kits, including C4a, C4bc (i.e., common
epitope for C4b and C4c), C4d, C3a, C3bc (i.e., common epitope for
Table 3
Oﬀ-label use of eculizumab − case reports and case series1,2.
Disease or disease group Medical condition Number of
papers1
Hemolytic uremic syndrome Typical HUS 7
Drug-induced HUS 3
Thrombotic microangiopathies
(TMA)
Posttransplant TMA 8
Stem cell transplantation-
associated TMA
6
Thrombotic
thrombocytopenic purpura
4
Drug- or viral-induced TMA 5
Kidney diseases C3 glomerulopathies (C3G) 17
IgA nephropathy 3
Cryoglobulin-induced
glomerulonephritis
1
Lupus nephritis 1
Scleroderma renal crisis 1
Antibody mediated rejection Kidney transplantation 17
Pancreas-kidney
transplantation
2
Lung and intestine
transplantation
2
Liver transplantation 1
Face transplantation 3
Antiphospholipid syndrome
(APS)
Catastrophic APS 10
Prophylactic use 2
Neuroimmunological diseases Neuromyelitis optica 2
Vasculopathy and vasculitis Malignant atrophic papulosis 2
ANCA-associated vasculitis 1
Haematological diseases Cold agglutinin disease 3
Warm IgG/M-mediated
hemolytic anemia
2
Sickle cell disease 2
Other Inherited CD59 deﬁciency 1
1See Supplementary Table 1 with all references included.
2The table is based on the Pubmed search (Terminal Complement Blockade OR C5-inhibition
OR eculizumab) (therapy OR treatment) NOT (atypical haemolytic uremic syndrome OR aHUS
OR paroxysmal nocturnal haemoglobinuria OR PNH). 459 hits were identiﬁed 23rd of
March 2017. Reviews, clinical trials, comments, animals and preclinical studies, reports
regarding PNH or aHUS and non-English written papers, were not included.
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iC3b, C3b and C3c), C3dg, Ba, Bb, C3bBbP, C5a and sC5b-9 (Fig. 3C). In
contrast to measuring single components it is of critical importance that
the sampling and storing conditions follow strict guidelines, i.e. by
collecting EDTA plasma, immediately placed on ice, centrifuged within
30 min and stored at −80 °C (Bergseth et al., 2013).
The choice of individual activation product assays(s) largely
depends on the purpose of the analysis. If it is of importance to
document the initial activation mechanism, measuring early compo-
nents can help to discriminate between CP/LP (C4 activation products)
and AP activation (FB activation products). However, more than one
pathway is involved in many conditions, and even if either the CP and/
or LP are primarily activated, the AP will usually be engaged activated
through the ampliﬁcation loop (Harboe et al., 2009). Thus, it is often
diﬃcult to reveal an exact activation mechanism by just measuring the
activation products. Speciﬁc inhibition of the recognition molecules
may be required in such cases.
Given their central role in fueling the ampliﬁcation loop and
eﬀector pathways, the screening of C3 and C5 activation products is
essential. Detection of the soluble form of the terminal complement
complex (sC5b-9) is probably the best assay to use as a single screening
assay. There are three main reasons for this: 1) It detects complement
activation to the very ﬁnal stage (activation of C9); 2) sC5b-9 has a
relatively long in vivo half-life (60 min) (Deppisch et al., 1990; Mollnes
1985) as compared to C5a. Although C5a is the main inﬂammatory
mediator of complement, it has a half-life of only approximately 1 min
due to rapid clearance and binding to the C5a receptors (Oppermann
and Gotze 1994; Wagner and Hugli 1984). sC5b-9 is by itself virtually
biologically inert, yet acts as a surrogate marker for the highly
proinﬂammatory C5a, since it hitherto has not been shown that sC5b-
9 can be formed in vivo without release of C5a; and 3) sC5b-9 is more
stable with respect to in vitro activation than the early component
fragments. The addition measurement of a C3 activation product may
be of importance as a supplement to sC5b-9 testing. This is of particular
interest when testing patients with a complement activation mediated-
disease that is treated with a C5 inhibitor like eculizumab, as for
example in the case of; e.g. in aHUS where C3 activation is ongoing,
whereas sC5b-9 formation is blocked by eculizumab.
It has to be considered that the degree of increased in vivo
concentration of a complement activation product will directly depend
on the present concentration of the native molecule. Thus, if C3 levels
are low due to activation and subsequent consumption, the ratio
between a C3 activation product and C3, e.g. C3dg/C3, might be a
more sensitive and robust marker of the degree of C3 activation, as
postulated more than 30 years ago (Nurnberger and Bhakdi 1984). This
principle of ratio applies in principle to activation of any component,
like in the case of C4 where the C4bc/C4 ratio was found to be
substantially more sensitive than the C4d/C4 ratio, although both ratios
were superior to the activation product or C4 alone (Nielsen et al.,
1995).
5.5. Autoantibodies to complement components
Autoantibodies to complement components may appear alone or as
part of an autoimmune or malignant disease, like anti-C1q antibodies in
systemic lupus erythematosus (Mahler et al., 2013) or anti-C1-INH
antibodies, mimicking genetic defect in C1-INH, in hematologic malig-
nancies (Cicardi and Zanichelli 2010). The pathogenesis of the latter is,
however, not related to complement, but to bradykinin release due to
ineﬃcient inhibition of the kallikrein-kinin system (Davis 2005). In
contrast, anti-FH antibodies may result in serious complement-
Fig. 2. Overview of major classes of complement diagnostic approaches. Whereas the traditional measurement of the plasma levels of intact complement components may provide evidence
for complement deﬁciencies or high consumptive turnover, the overall information is rather limited. Including activation fragments in the analysis enables conclusions about the
activation status and/or involvement of individual initiation or eﬀector pathways. Similarly, the detection of complement deposition on cells and tissues by immunohistochemistry can
provide information about the type and localization of complement activity. Finally, functional assays based on either hemolytic activity (i.e., CH50, AH50) or detection of membrane
attack complex (MAC) formation by ELISA allow for the measurement of total complement activity in patient serum or plasma dependent on pathway-speciﬁc triggers. In addition, to the
methods shown here, genetic analyses become increasingly prevalent in the complement diagnostics ﬁeld. Abbreviations: MBL, mannose-binding lectin; RRBC, rabbit red blood cells;
SRBC, sheep red blood cells.
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mediated diseases due to uncontrolled activation of the AP, similar to
genetic FH dysfunction leading to aHUS or C3G (Durey et al., 2016). It
is important to distinguish the genetic FH deﬁciency from autoantibo-
dies in aHUS due to diﬀerent treatment approaches. The genetic form
usually responds eﬃciently to eculizumab, but not to plasma exchange
and immunosuppression, which are alternative options to eculizumab
in the treatment of antibody-induced aHUS to reduce the level of
autoantibodies (Chiodini et al., 2014; Loirat et al., 2015).
5.6. Cell surface expression and tissue deposition of complement
Cell surfaces are the focal area of complement activation disorders.
The absence or reduced expression of membrane-bound complement
regulators can contribute to increased complement activation, which
leads to the deposition of opsonins (e.g., C3b, C4b) and eﬀectors (e.g.,
C5b-9n). Measuring complement components and activation products
directly on a cell surface can therefore provide valuable information.
Flow cytometry is the standard technique for the diagnosis of PNH, by
detecting reduced levels of CD55 and CD59 on blood cells. Detection of
complement activation products like C3d and C4d on red cells using
ﬂow cytometry has also been used to evaluate in vivo complement
activation in e.g. autoimmune diseases and trauma (Kao et al., 2010;
Muroya et al., 2014). Deposition of various complement components in
the glomeruli may help in the diagnosis of glomerulopathies (Cook and
Pickering 2015) and peritubular capillary deposition of C4d, as
measured by immunoﬂuorescence in frozen sections, is one of the
Banﬀ criteria for diagnosis of acute antibody-mediated renal rejection
(Solez et al., 2008; Stites et al., 2015).
5.7. Genetic studies
During the past two decades genetic studies have substantially
improved our understanding of etiology and pathogenesis of comple-
ment-mediated diseases and genetic tests have meanwhile been estab-
lished in routine diagnostics. Diseases such as aHUS, C3G and AMD are
closely associated with genetic variants or defects leading to loss-of-
function of the regulatory proteins like FH, FI, MCP or gain-of-function
of C3 or FB (de Cordoba 2015; De Vriese et al., 2015; Harris et al., 2012;
Heurich et al., 2011; Le et al., 2010; Roumenina et al., 2011; Servais
et al., 2012). Of particular importance is a rapid diagnosis of pediatric
aHUS in order to distinguish it from other thrombotic microangiopa-
thies and initiate the correct therapy. Many laboratories now oﬀer both
single gene sequencing as well as ‘diagnostic packages’.
5.8. Assays to monitor treatment with eculizumab
The availability of eculizumab has changed the therapeutic land-
scape for both PNH and aHUS, and standard treatment plans have
meanwhile been established in many cases. However, there are several
reasons why treatment with eculizumab would largely beneﬁt from an
individualized therapy regimen for each patient. First of all, excessive
dosages should be avoided due to the high cost of the drug (sometimes
exceeding $500,000 per year and patient). The pharmacokinetics of
eculizumab may diﬀer between individuals and between diﬀerent
disease conditions, and the concentration of C5 varies substantially
between individuals as does the blood volume. Thus, the dose required
for a full blockade of C5 activity, which is the primary aim of the
therapy, will vary considerably between patients. The doses admini-
strated are based on generalized guidelines for all adults adapted
guidelines and similarly generalized reduced doses for children
(< 40 kg). Unfortunately, there is no consensus yet on the best option
to follow these patients with analyses that can guide an individualized
follow-up therapy.
Tests for total complement activity, including lytic CH50 and ELISA-
based C5b-9 formation (total complement screen Wieslab®), have been
used to follow patients and revealed a substantial diﬀerence in the
Table 4
Complement tests in clinical diagnostics and treatment monitoring.
Type of assay Examples Indication and information Sample treatment
Screen of total serum
complement activity in
vitro
Lytic CH50 and AH50. ELISA-
based CP1, LP and AP
complement screen
Detect complement deﬁciency. Monitoring complement
inhibitory therapy. Readout is lysis or C5b-9 formation.
Normal activity indicates intact components of the actual
pathway
Fresh serum without anticoagulant
immediately stored at −80 °C
Single protein quantiﬁcation E.g. C1q, C1-Inhibitor, C3, C4. Detect complement deﬁciency, e.g. HAE type I. General
information on complement synthesis, activation, acute phase
Normal serum (most tests are not
inﬂuenced by in vitro activation)
Single functional activity E.g. C1-Inhibitor, FH Normal protein concentration does not exclude functional
defects, e.g. HAE type II, FH defects in several diseases
Fresh serum without anticoagulant
immediately stored at −80 °C
Activation products E.g. sC5b-9, C5a, C3a, C3bc,
C3d, C4a, C4d, Ba, Bb
Detect activation of a certain component. In vivo useful for
diagnostics, complement activity and monitoring complement
inhibitory therapy
EDTA plasma. Sample kept at 4 °C,
centrifuged within 30 min and stored at
−80 °C
Autoantibodies E.g. anti-FH, −C1q Interference with function (e.g. aHUS for FH) Normal serum or plasma
Cell and tissue expression of
complement
E.g. CD55 and CD59 on red cells
(FC), C4d and C5b-9 in kidneys
(IF, IHC)
Diagnosis of PNH (CD55, CD59). Acute antibody-mediated
kidney rejection (C4d in tubuli). C3G (C5b-9 in glomeruli
Fresh EDTA whole blood for FC. Frozen
tissue section for IF and formalin tissue for
IHC
Genetic assays Screening for SNPs in
complement genes,
complotypes.
Detect risk of developing complement-mediated diseases
including aHUS, C3G and AMD. “Disease packages”
Fresh EDTA whole blood or frozen EDTA
blood sent on dry ice
Other assays with speciﬁc focus
on monitoring treatment
Detection of eculizumab by
ELISA; endothelial cell
activation;
Level of eculizumab suﬃcient to block complement. ELISA
coated with C5 (detecting binding of eculizumab), captured
with anti-C5 detecting the level of eculizumab-C5 complexes.
Mass spectrometry detection of bound and free eculizumab
Normal serum or plasma analyzed within a
few days or stored at −20 °C. Independent
on in vitro activation
Mass spectrometry
1Abbreviations: CP (classical pathway), LP (lectin pathway), AP (alternative pathway), HAE (hereditary angioedema), FC (ﬂow cytometry), IF (immunoﬂuorescence), IHC
(immunohistochemistry), aHUS (atypical hemolytic uremic syndrome), C3G (C3 glomerulopathies), AMD (age-related macular degeneration).
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interval before complement activity starts to increase after an infusion.
This varies from days to several weeks, and these tests should be useful
as indicators of suﬃcient dose given and when it is time for a new dose
(Cugno et al., 2014; Gustavsen et al., 2017; Peﬀault de Latour et al.,
2014; Volokhina et al., 2015b; Wehling et al., 2016). An alternative
“functional” assay tested the residual activity of C5 present in a serum
by activation the serum in vitro with subsequent quantiﬁcation of
soluble TCC (sC5b-9) (Riedl et al., 2016). This is a more laborious test
than the screening ELISA and it remains to be shown whether it will
have a place in routine diagnostics.
Other tests have been developed for speciﬁc investigation of the
eﬀects of eculizumab, including an elegant study using deposition of
C5b-9 on endothelial cells as readout (Noris et al., 2014). Furthermore,
an ELISA assay for measuring eculizumab-C5 complexes has been
developed by capturing C5 by anti-C5 on the plate and detecting the
complex by anti-IgG4 (Hallstensen et al., 2014). By this assay it was
shown that eculizumab hardly passed the placenta from the mother to
the child since only trace amounts of the complexes was found in the
umbilical cord and plasma of the newborn and the newborn’s serum
had normal complement activity. This observation was conﬁrmed in a
later study (Gustavsen et al., 2017). This assay can also be used to test
whether eculizumab or C5 is in excess in a sample, by in vitro adding
puriﬁed C5 or eculizumab, respectively, and determine whether the
complexes increases. These assays are, however, relatively demanding
and thus less suitable for rapid routine testing.
Recently an ELISA has been developed for the detection of
eculizumab in patient samples based on eculizumab binding to C5-
coated microtiter-wells and detected by anti-Ig antibodies (Gatault
et al., 2015; Peﬀault de Latour et al., 2014; Volokhina et al., 2017).
These are in-house assays and it is uncertain how much of the total
eculizumab in the sample is detected. Excess of free eculizumab will
certainly bind, but the equilibrium of antigen-antibody reaction will
imply a continuous shift of eculizumab molecules between the C5 on
the surface and in ﬂuid phase, and the binding to surface-bound C5 will
ﬁnally depend on the molar ratio between the molecules. An assay
based on mass spectrometry was, however, recently published and
documented to detect the total amount of eculizumab present in the
sample as measured by the light chain of the IgG2/4 chimera (Ladwig
et al., 2016). This assay is probably the most exact assay published so
far for measuring the total amount of eculizumab in the sample, but it
does not discriminate between the bound and the free antibody in the
current version of the assay; however, discrimination will probably be
possible upon modiﬁcation of the assay.
A couple of issues have been raised with respect to blockage of C5
by eculizumab. First, it is known that a C5 mutant predominantly
observed in Asia confers resistance to eculizumab (Nishimura et al.,
2014). Second, it has been shown that eculizumab prevent convertase-
mediated C5 activation but not direct cleavage by thrombin
(Riedemann et al., 2017) and that there is a residual activity in the
alternative hemolytic assay when the complement activation is parti-
cularly strong (Harder et al., 2017). These observations illustrate
potential challenges in the design and monitoring of eculizumab
therapy yet the clinical relevance remains to be further explored.
It is evident that immunological assays are prone to pitfalls, and the
testing of samples from patients treated with eculizumab is no excep-
tion. It has been previously claimed in a letter in Blood that treatment
Fig. 3. Illustration of diﬀerent approaches to test terminal complement activation by TCC formation (MAC or sC5b-9). (A) The total complement activity present in serum tested in the classical,
lectin and alternative pathways using ELISA. This screening assay determines the functional activity of all complement components by in vitro generation of C5b-9 deposited on the solid-
phase after incubation of serum in the wells. Read-out is detection of a C9 neoepitope exposed in C9 only after activation. This test is indicated for screening of complement deﬁciencies.
(B) Samples from patients treated with the C5 inhibitor eculizumab can be tested in the screening assay described above. If C5 is in excess (a) it will be detected as activity in the screening
test, if all C5 molecules are bound either uni- (b) or bi-valently (c) there will be no activity in the screening test. If eculizumab is present in excess (d) the result will be the same as for (b)
and (c). (C) ELISA assay for detection of the ﬂuid-phase generated C5b-9 (sC5b-9). This complex can be detected in increased amounts in plasma from patients with in vivo activation of
complement and should be low or undetectable in patients treated with eculizumab (similar as for a homozygous C5 deﬁciency).
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with eculizumab would not prevent formation of C5a in vivo when the
authors observed that C5a, but not sC5b-9, increased after infusion of
eculizumab (Burwick et al., 2014). This was, in our opinion, intuitively
contradictory and could not be explained by established molecular
mechanisms concerning the cleavage of C5. We therefore investigated
this phenomenon in detail and showed that the unexpected ﬁnding was
indeed caused by a false positive reaction with the speciﬁc C5a assay
the authors used (provided by BD). We conﬁrmed the reported results
using the same assay, whereas we found no detectable C5a in two other
well established C5a assays (from Hycult and RND) (Volokhina et al.,
2015a). Binding of eculizumab to C5 induces a C5a neoepitope which is
falsely detected as free C5a in the BD C5a assay. Thus, assays based on
monoclonal antibodies to detect activation of complement should be
carefully investigated, in particular with respect to C5 in the case of
eculizumab, but also as a general principle to avoid misinterpretations
of important tests used to follow-up of patients. Complement activation
products are indeed important not only in diagnostics, but also in
therapy monitoring. Thus, in the case of inhibiting C5, both the
functional tests and the detection of activation products beyond C5
(i.e. C5a and sC5b-9) should be negative.
In conclusion, prospective studies comparing diﬀerent assays in the
evaluation of patients treated with eculizumab, and with other comple-
ment inhibitors in the future, are necessary to provide robust guidelines
for optimal and individualized therapies in complement-mediated
diseases.
5.9. Quality and standardization
Since many of the complement tests have not yet been oﬃcially
approved and various laboratories use modiﬁcations of previously
described tests or use their own in-house assays, there is a deﬁnite
need for improvement of test quality and for standardization of the
assays. Therefore, the International Complement Society (ICS) has
established a committee working on standardization and external
quality assessment (EQA) of complement diagnostics. This entity is an
oﬃcial sub-committee for the Standardization and Quality Assessment
of Complement Measurements, belonging to the IUIS Quality
Assessment and Standardization Committee (http://www.iuisonline.
org/index.php?option=com_content&view=article&id=64&Itemid=
69). This committee is active in EQA with a number of international
complement laboratories being involved, and it will become even more
important in the future to guide recommendations of complement tests
both for diagnostics and for treatment monitoring. Furthermore the
European Complement Network has established a link on their website
to laboratories oﬀering routine complement diagnostics across country
borders (http://www.ecomplement.org/).
6. Conclusions and perspectives
The status of complement in the clinical arena has profoundly
changed, thanks to new biomedical and molecular insight in its disease
involvement and the availability of the ﬁrst complement-targeted drugs
in the clinic or in clinical trials. Many of the initial challenges and
reservations could be diminished, giving rise to a new surge in the
development of new drug candidates and the identiﬁcation of interest-
ing potential indications. Owing to the vast and constantly growing
diversity in disease processes, potential indications and emerging
treatment options in complement-mediated disorders, knowing a
patient’s distinct complement proﬁle will become ever more important.
The recent improvements and diversiﬁcation in diagnostic tools to
determine the concentration, function, activity and alteration of
complement cascade components are important steps in this context.
Genetic tools in particular have changed the ﬁeld substantially and may
help narrowing down disease spectra, choosing appropriate treatment
options and selecting the best patient population to be enrolled in
clinical trials. This will be critical for advancing complement even
further to the clinic. Diagnostic centers oﬀering complement tests are
already emerging in many regions. However, even the best diagnostic
tool is a blunt instrument without the capability of correctly interpret-
ing the test results and tailoring the treatment strategy accordingly.
Careful standardization eﬀorts as well as close collaboration and
scientiﬁc exchange between academic researchers, industrial scientists,
diagnostic and clinical experts will therefore be critical for achieving
the next stage in complement-targeted therapies.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.molimm.2017.05.013.
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